{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T15:48:45Z","timestamp":1792165725420,"version":"4.4.0"},"reference-count":37,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T00:00:00Z","timestamp":1790121600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Cell"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.ccell.2026.09.011","type":"journal-article","created":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T15:02:56Z","timestamp":1792162976000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Firmonertinib in advanced non-small cell lung cancer with epidermal growth factor receptor P-loop and \u03b1C-helix compressing mutations"],"prefix":"10.1016","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8554-1185","authenticated-orcid":false,"given":"Xiuning","family":"Le","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanqiu","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Planchard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Spira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingling","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xingya","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shirish","family":"Gadgeel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natasha","family":"Leighl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junqiang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidetoshi","family":"Hayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makoto","family":"Nishio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julien","family":"Mazieres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrianus Johannes","family":"de Langen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurice","family":"P\u00e9rol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiyotaka","family":"Yoh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin D.","family":"Forster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasushi","family":"Goto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"de Miguel Luken","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando Fabio","family":"Franco Perez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quincy","family":"Chu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sagun","family":"Parakh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monique B.","family":"Nilsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianhua","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cunlin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nichole","family":"Baio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luna","family":"Musib","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zineb","family":"Mounir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcin","family":"Kowanetz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shirley","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Yea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerry","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stuart","family":"Lutzker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John V.","family":"Heymach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oscar","family":"Juan-Vidal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan W.","family":"Riess","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ccell.2026.09.011_bib1","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.cllc.2025.02.008","article-title":"Racial Diversity and Co-Mutational Analysis of Biologically Relevant Alterations in EGFR Mutant Lung Cancers","volume":"26","author":"Gutta","year":"2025","journal-title":"Clin. Lung Cancer"},{"key":"10.1016\/j.ccell.2026.09.011_bib2","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1038\/bjc.2013.721","article-title":"First-line gefitinib in Caucasian EGFR mutation-positive NSCLC patients: a phase-IV, open-label, single-arm study","volume":"110","author":"Douillard","year":"2014","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.ccell.2026.09.011_bib3","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1097\/JTO.0000000000000033","article-title":"A prospective, molecular epidemiology study of EGFR mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology (PIONEER)","volume":"9","author":"Shi","year":"2014","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.ccell.2026.09.011_bib4","doi-asserted-by":"crossref","first-page":"8919","DOI":"10.1158\/0008-5472.CAN-04-2818","article-title":"Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications","volume":"64","author":"Kosaka","year":"2004","journal-title":"Cancer Res."},{"key":"10.1016\/j.ccell.2026.09.011_bib5","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1038\/s41586-021-03898-1","article-title":"Structure-based classification predicts drug response in EGFR-mutant NSCLC","volume":"597","author":"Robichaux","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.ccell.2026.09.011_bib6","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2020.610923","article-title":"Concurrent Genetic Alterations and Other Biomarkers Predict Treatment Efficacy of EGFR-TKIs in EGFR-Mutant Non-Small Cell Lung Cancer: A Review","volume":"10","author":"Guo","year":"2020","journal-title":"Front. Oncol."},{"key":"10.1016\/j.ccell.2026.09.011_bib7","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.semcancer.2019.09.015","article-title":"Rare epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer","volume":"61","author":"Harrison","year":"2020","journal-title":"Semin. Cancer Biol."},{"key":"10.1016\/j.ccell.2026.09.011_bib8","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/j.jtho.2024.12.012","article-title":"Decoding the Clinical and Molecular Signatures of EGFR Common, Compound, and Uncommon Mutations in NSCLC: A Brief Report","volume":"20","author":"Tavernari","year":"2025","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.ccell.2026.09.011_bib9","unstructured":"National Comprehensive Cancer Network (2025). NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae): Non-Small Cell Lung Cancer version 8.2025. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/nscl.pdf."},{"key":"10.1016\/j.ccell.2026.09.011_bib10","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/S1470-2045(14)71173-8","article-title":"Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials","volume":"16","author":"Yang","year":"2015","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ccell.2026.09.011_bib11","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1016\/S1470-2045(15)00026-1","article-title":"Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6","volume":"16","author":"Yang","year":"2015","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ccell.2026.09.011_bib12","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1056\/NEJMoa1713137","article-title":"Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer","volume":"378","author":"Soria","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ccell.2026.09.011_bib13","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1200\/JCO.19.00931","article-title":"Osimertinib for Patients With Non-Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Multicenter, Open-Label, Phase II Trial (KCSG-LU15-09)","volume":"38","author":"Cho","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ccell.2026.09.011_bib15","article-title":"Osimertinib in NSCLC With Atypical EGFR-Activating Mutations: A Retrospective Multicenter Study","volume":"4","author":"Ji","year":"2023","journal-title":"JTO Clin. Res. Rep."},{"key":"10.1016\/j.ccell.2026.09.011_bib17","doi-asserted-by":"crossref","first-page":"e14","DOI":"10.1016\/j.jtho.2022.09.037","article-title":"Furmonertinib is an oral, irreversible, highly brain-penetrant pan-EGFR inhibitor with activity against classical and atypical EGFR mutations [PP01.11]","volume":"18","author":"Musib","year":"2023","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.ccell.2026.09.011_bib18","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1016\/S2213-2600(22)00168-0","article-title":"Furmonertinib (AST2818) versus gefitinib as first-line therapy for Chinese patients with locally advanced or metastatic EGFR mutation-positive non-small-cell lung cancer (FURLONG): a multicentre, double-blind, randomised phase 3 study","volume":"10","author":"Shi","year":"2022","journal-title":"Lancet Respir. Med."},{"key":"10.1016\/j.ccell.2026.09.011_bib19","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1016\/j.jtho.2020.01.010","article-title":"Safety, Clinical Activity, and Pharmacokinetics of Alflutinib (AST2818) in Patients With Advanced NSCLC With EGFR T790M Mutation","volume":"15","author":"Shi","year":"2020","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.ccell.2026.09.011_bib20","doi-asserted-by":"crossref","first-page":"S49","DOI":"10.1016\/j.jtho.2023.09.033","article-title":"A Phase 1b study of furmonertinib, an oral, brain penetrant, selective EGFR inhibitor, in patients with advanced NSCLC with EGFR exon 20 insertions [OA03.04]","volume":"18","author":"Han","year":"2023","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.ccell.2026.09.011_bib21","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1016\/j.jtho.2024.09.019","article-title":"FURTHER: A global, randomized study of firmonertinib at two dose levels in TKI-naive, advanced NSCLC with EGFR PACC mutations [PL04.07]","volume":"19","author":"Le","year":"2024","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.ccell.2026.09.011_bib22","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1158\/2159-8290.CD-17-0151","article-title":"AACR Project GENIE: Powering Precision Medicine Through An International Consortium [version 18]","volume":"7","year":"2017","journal-title":"Cancer Discov."},{"key":"10.1016\/j.ccell.2026.09.011_bib27","doi-asserted-by":"crossref","first-page":"i28","DOI":"10.1093\/annonc\/mdx705","article-title":"Molecular mechanisms of acquired resistance to third-generation EGFR-TKIs in EGFR T790M-mutant lung cancer","volume":"29","author":"Ricordel","year":"2018","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ccell.2026.09.011_bib24","article-title":"First report of furmonertinib as a first-line treatment in advanced lung adenocarcinoma patients harboring EGFR exon 20 insertion mutations after the kinase domain alphaC-helix: Two case reports and a literature review","volume":"102","author":"Han","year":"2023","journal-title":"Medicine (Baltim.)"},{"key":"10.1016\/j.ccell.2026.09.011_bib23","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/S1470-2045(12)70087-6","article-title":"Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b\/3 randomised trial","volume":"13","author":"Miller","year":"2012","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ccell.2026.09.011_bib25","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S1470-2045(11)70393-X","article-title":"Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial","volume":"13","author":"Rosell","year":"2012","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ccell.2026.09.011_bib26","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aan6566","article-title":"A method of high-throughput functional evaluation of EGFR gene variants of unknown significance in cancer","volume":"9","author":"Kohsaka","year":"2017","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.ccell.2026.09.011_bib38","doi-asserted-by":"crossref","first-page":"e527","DOI":"10.1016\/j.cllc.2025.06.005","article-title":"Clinical Outcomes of Compound EGFR Mutations in Non-Small Cell Lung Cancer: A National, Retrospective, Multicenter Study","volume":"26","author":"Atlagh","year":"2025","journal-title":"Clin. Lung Cancer"},{"key":"10.1016\/j.ccell.2026.09.011_bib28","doi-asserted-by":"crossref","first-page":"3340","DOI":"10.1158\/1078-0432.CCR-22-3146","article-title":"Early Clearance of Plasma Epidermal Growth Factor Receptor Mutations as a Predictor of Outcome on Osimertinib in Advanced Non-Small Cell Lung Cancer; Exploratory Analysis from AURA3 and FLAURA","volume":"29","author":"Gray","year":"2023","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ccell.2026.09.011_bib29","doi-asserted-by":"crossref","first-page":"CT017","DOI":"10.1158\/1538-7445.AM2024-CT017","article-title":"FLAURA2: exploratory analysis of baseline (BL) and on-treatment plasma EGFRm dynamics in patients (pts) with EGFRm advanced NSCLC treated with first-line (1L) osimertinib (osi) \u00b1 platinum-pemetrexed [abstract]","volume":"84","author":"J\u00e4nne","year":"2024","journal-title":"Cancer Res."},{"key":"10.1016\/j.ccell.2026.09.011_bib30","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1056\/NEJMoa2004407","article-title":"Tepotinib in Non-Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations","volume":"383","author":"Paik","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ccell.2026.09.011_bib31","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1016\/j.jtho.2023.05.021","article-title":"Early Circulating Tumor DNA Dynamics and Efficacy of Lorlatinib in Patients With Treatment-Naive, Advanced, ALK-Positive NSCLC","volume":"18","author":"Soo","year":"2023","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.ccell.2026.09.011_bib39","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.1158\/1078-0432.CCR-24-3612","article-title":"ctDNA Clearance as an Early Indicator of Improved Clinical Outcomes in Advanced NSCLC Treated with TKI: Findings from an Aggregate Analysis of Eight Clinical Trials","volume":"31","author":"Andrews","year":"2025","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ccell.2026.09.011_bib32","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1056\/NEJMoa2511065","article-title":"Sevabertinib in Advanced HER2-Mutant Non-Small-Cell Lung Cancer","volume":"393","author":"Le","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ccell.2026.09.011_bib33","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.jtho.2024.09.1385","article-title":"High-Dose Furmonertinib in Patients With EGFR-Mutated NSCLC and Leptomeningeal Metastases: A Prospective Real-World Study","volume":"20","author":"Chen","year":"2025","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.ccell.2026.09.011_bib34","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1186\/s12916-023-02865-z","article-title":"Central nervous system efficacy of furmonertinib (AST2818) in patients with EGFR T790M mutated non-small cell lung cancer: a pooled analysis from two phase 2 studies","volume":"21","author":"Hu","year":"2023","journal-title":"BMC Med."},{"key":"10.1016\/j.ccell.2026.09.011_bib35","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1001\/jamaoncol.2023.5013","article-title":"First-Line Osimertinib for Previously Untreated Patients With NSCLC and Uncommon EGFR Mutations: The UNICORN Phase 2 Nonrandomized Clinical Trial","volume":"10","author":"Okuma","year":"2024","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.ccell.2026.09.011_bib36","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1200\/JCO-24-02007","article-title":"Pragmatic Randomized Study of Afatinib Versus Chemotherapy for Patients With Non-Small Cell Lung Cancer With Uncommon Epidermal Growth Factor Receptor Mutations: ACHILLES\/TORG1834","volume":"43","author":"Miura","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ccell.2026.09.011_bib37","unstructured":"GILOTRIF\u00ae (afatinib tablets). (2022). Prescribing Information. Ridgefield, CT: Boehringer Ingelheim. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/201292s017lbl.pdf. Last updated April 2022. Accessed October 7, 2026."}],"container-title":["Cancer Cell"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1535610826004307?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1535610826004307?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T15:03:01Z","timestamp":1792162981000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1535610826004307"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":37,"alternative-id":["S1535610826004307"],"URL":"https:\/\/doi.org\/10.1016\/j.ccell.2026.09.011","relation":{},"ISSN":["1535-6108"],"issn-type":[{"value":"1535-6108","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Firmonertinib in advanced non-small cell lung cancer with epidermal growth factor receptor P-loop and \u03b1C-helix compressing mutations","name":"articletitle","label":"Article Title"},{"value":"Cancer Cell","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ccell.2026.09.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.ccell.2026.08.003","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}